 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
Farnesyltransferase complex with tetrahydropyridine inhibitors
|
|
Structure:
|
 |
Protein farnesyltransferase alpha subunit. Chain: a. Fragment: residue 55-369. Synonym: caax farnesyltransferase alpha subunit, ras proteins prenyltransferase alpha, ftase-alpha. Engineered: yes. Protein farnesyltransferase beta subunit. Chain: b. Fragment: residue 22-423.
|
|
Source:
|
 |
Rattus norvegicus. Norway rat. Organism_taxid: 10116. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108.
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
3.20Å
|
R-factor:
|
0.329
|
R-free:
|
0.375
|
|
|
Authors:
|
 |
S.L.Gwaltney Ii,S.J.O'Conner,L.T.Nelson,G.M.Sullivan, H.Imade,W.Wang,L.Hasvold,Q.Li,J.Cohen,W.Z.Gu
|
|
Key ref:
|
 |
S.L.Gwaltney
et al.
(2003).
Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.
Bioorg Med Chem Lett,
13,
1363-1366.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
22-Nov-02
|
Release date:
|
07-Jan-03
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chains A, B:
E.C.2.5.1.58
- Protein farnesyltransferase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
|
 |
 |
 |
 |
 |
Farnesyl diphosphate
Bound ligand (Het Group name = )
matches with 57.00% similarity
|
+
|
protein-cysteine
|
=
|
S-farnesyl protein
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Cofactor:
|
 |
Magnesium; Zinc
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chain A:
E.C.2.5.1.59
- Protein geranylgeranyltransferase type I.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Geranylgeranyl diphosphate + protein-cysteine = S-geranylgeranyl- protein + diphosphate
|
 |
 |
 |
 |
 |
Geranylgeranyl diphosphate
Bound ligand (Het Group name = )
matches with 48.00% similarity
|
+
|
protein-cysteine
|
=
|
S-geranylgeranyl- protein
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Cofactor:
|
 |
Zinc
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
protein complex
|
2 terms
|
 |
|
Biological process
|
response to inorganic substance
|
11 terms
|
 |
|
Biochemical function
|
catalytic activity
|
12 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Bioorg Med Chem Lett
13:1363-1366
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.
|
|
S.L.Gwaltney,
S.J.O'Connor,
L.T.Nelson,
G.M.Sullivan,
H.Imade,
W.Wang,
L.Hasvold,
Q.Li,
J.Cohen,
W.Z.Gu,
S.K.Tahir,
J.Bauch,
K.Marsh,
S.C.Ng,
D.J.Frost,
H.Zhang,
S.Muchmore,
C.G.Jakob,
V.Stoll,
C.Hutchins,
S.H.Rosenberg,
H.L.Sham.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Inhibitors of farnesyltransferase are effective against a variety of tumors in
mouse models of cancer. Clinical trials to evaluate these agents in humans are
ongoing. In our effort to develop new farnesyltransferase inhibitors, we have
discovered bioavailable aryl tetrahydropyridines that are potent in cell
culture. The design, synthesis, SAR and biological properties of these compounds
will be discussed.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.Berezin,
and
S.Achilefu
(2007).
Novel synthon for incorporating 1,3-dimethyl imidazolium group into molecular architecture.
|
| |
Tetrahedron Lett, 48,
1195-1199.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
| |